Systematic review of the efficacy, effectiveness and safety of cell‐based seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age-Reference-Cited by-同舟云学术

Systematic review of the efficacy, effectiveness and safety of cell‐based seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age

Published:2022-02-08 Issue:3 Volume:33 Page:
ISSN:1052-9276
Container-title:Reviews in Medical Virology
language:en
Short-container-title:Reviews in Medical Virology

Author:

Jordan Karen¹^ORCID,Murchu Eamon O.¹²,Comber Laura¹,Hawkshaw Sarah¹,Marshall Liam¹,O’Neill Michelle¹,Teljeur Conor¹,Harrington Patricia¹,Carnahan Annasara³⁴,Pérez‐Martín Jaime Jesús⁴⁵,Robertson Anna Hayman⁴⁶,Johansen Kari⁴⁷,Jonge Jorgen de⁴⁸,Krause Tyra⁴⁹,Nicolay Nathalie⁴⁷,Nohynek Hanna⁴¹⁰,Pavlopoulou Ioanna⁴¹¹¹²,Pebody Richard⁴¹³,Penttinen Pasi⁴⁷,Soler‐Soneira Marta⁴¹⁴,Wichmann Ole⁴¹⁵,Ryan Máirín¹¹⁶

Affiliation:

1. Health Technology Assessment Health Information and Quality Authority (HIQA) Dublin Ireland

2. Department of Health Policy & Management School of Medicine Trinity College Dublin Dublin Ireland

3. Public Health Agency of Sweden Solna Sweden

4. European Centre for Disease Prevention and Control EU/EEA National Immunisation Technical Advisory Group (NITAG) collaboration on newer and enhanced inactivated seasonal influenza vaccines Stockholm Sweden

5. General Directorate of Public Health and Addictions IMIB‐Arrixaca Murcia University Murcia Spain

6. Division of Infection Control and Environmental Health Norwegian Institute of Public Health Oslo Norway

7. European Centre for Disease Prevention and Control Stockholm Sweden

8. Center for Infectious Disease Control National Institute for Public Health and the Environment Bilthoven the Netherlands

9. Statens Serum Institut Copenhagen Denmark

10. Finnish Institute for Health and Welfare Helsinki Finland

11. School of Health Sciences Faculty of Nursing Pediatric Research Laboratory National and Kapodistrian University of Athens Athens Greece

12. National Advisory Committee on Immunisation Hellenic Ministry of Health Athens Greece

13. Institute of Epidemiology & Health University College London London UK

14. Vigilancia de Enfermedades Prevenibles por Vacunación Centro Nacional de Epidemiología Instituto de Salud Carlos III Ministerio de Ciencia e Innovación Madrid Spain

15. Immunization Unit Robert Koch‐Institute Berlin Germany

16. Department of Pharmacology & Therapeutics Trinity College Dublin Trinity. Health Sciences Dublin Ireland

Funder

European Centre for Disease Prevention and Control

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rmv.2332

Reference58 articles.

1. Influenza vaccination and absenteeism among healthy working adults: a cost‐benefit analysis;Ferro A;Annali di igiene: medicina preventiva e di comunita,2020

2. Economic burden of seasonal influenza in the United States

3. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing

4. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

5. Interim estimates of 2014/2015 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015;Skowronski DM;Eur Commun Dis Bull (Euro Surveill: Bulletin Europeen sur les maladies transmissibles),2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can the Internal Nasal Valves Method Be a Game Changer for Preventing Respiratory Tract Infections?;International Journal of Translational Medical Research and Public Health;2024-07-25

2. Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review;Pharmaceuticals;2024-06-19

3. Estimates of Seasonal Influenza Burden That Could Be Averted by Improved Influenza Vaccines in the Australian Population Aged Under 65 Years, 2015–2019;Influenza and Other Respiratory Viruses;2024-04

4. Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18–60 years: A double-blind, non-inferiority, randomized controlled trial;Vaccine;2024-04

5. Repeated vaccination with homologous influenza hemagglutinin broadens human antibody responses to unmatched flu viruses;2024-03-29